Spero Therapeutics (SPRO) EV to CFO (2017 - 2026)

Spero Therapeutics (SPRO) has reported EV to CFO for 10 consecutive years, with 14.52 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to CFO fell 94.93% year-over-year to 14.52; the trailing twelve-month figure through Jun 2026 stood at 3.97 (up 197.43% YoY), and the FY2025 full-year result was 7.22, down 4966.29% from the prior year.
• EV to CFO eased to 14.52 in Q2 2026 per SPRO's latest filing, from 5.0 in the prior quarter.
• Across five years, EV to CFO topped out at 5.0 in Q1 2026 and bottomed at 36.85 in Q3 2022.
• Historically, EV to CFO has averaged 3.59 across 5 years, with a median of 0.21 in 2024.
• The widest YoY moves for EV to CFO: up 1295.33% in 2025, down 7544.54% in 2025.
• Over 5 years, EV to CFO stood at 0.99 in 2022, then jumped by 90.91% to 0.09 in 2023, then slumped by 58.48% to 0.14 in 2024, then slumped by 7544.54% to 10.92 in 2025, then sank by 32.94% to 14.52 in 2026.
• According to Business Quant data, EV to CFO over the past three periods registered 14.52, 5.0, and 10.92 for Q2 2026, Q1 2026, and Q4 2025 respectively.